
Kerry Group plc
Kerry
Kerry Group is a global leader in taste, nutrition, and pharmaceutical excipients, headquartered in Tralee, County Kerry, Ireland. Founded in 1972 and listed on the Euronext Dublin (ISEQ: KRZ) and London Stock Exchange (LSE: KYGA), Kerry generates over €8 billion in annual revenue with 21,000+ employees across 150+ manufacturing sites worldwide. Its Sheffield Bio-Science division is a critical supplier of cell culture media supplements and high-purity pharmaceutical lactose for the global biopharmaceutical industry.
Strengths: Sheffield Bio-Science — proprietary fermentation technology for animal-origin-free cell culture supplements; global manufacturing footprint with 150+ facilities providing multi-region supply redundancy; deep pharmaceutical excipient portfolio including high-specification lactose for dry powder inhalers and direct compression formulations; vertically integrated dairy supply chain ensuring raw material security and traceability; R&D investment of €300M+ annually across global innovation centers.
Weaknesses: revenue dominated by food ingredients — pharma excipients represent a minority of group sales, limiting strategic focus; manufacturing concentration in Europe with fewer pharma-dedicated facilities in North America and Asia; limited presence in lipid nanoparticles and advanced drug delivery systems compared to Croda and Evonik.Read MoreShow Less
Strengths: Sheffield Bio-Science — proprietary fermentation technology for animal-origin-free cell culture supplements; global manufacturing footprint with 150+ facilities providing multi-region supply redundancy; deep pharmaceutical excipient portfolio including high-specification lactose for dry powder inhalers and direct compression formulations; vertically integrated dairy supply chain ensuring raw material security and traceability; R&D investment of €300M+ annually across global innovation centers.
Weaknesses: revenue dominated by food ingredients — pharma excipients represent a minority of group sales, limiting strategic focus; manufacturing concentration in Europe with fewer pharma-dedicated facilities in North America and Asia; limited presence in lipid nanoparticles and advanced drug delivery systems compared to Croda and Evonik.
Listed market data
KRZ · EURONEXT · weeklyHistory →- Market cap
- $15.7 B
- Share price
- EUR 97.75
- 1Y change
- +25.1%
- Recent change
- -1.2%
- Since first close
- +27.4%
11-02 → 11-03
from 2025-09
Financial history
Full market history- 2026-11EUR 97.75$15.7 B-0.6%
- 2026-10EUR 98.35$15.8 B+15.4%
- 2026-09EUR 85.20$13.7 B+1.4%
- 2026-08EUR 84.00$13.5 B+1.4%
- 2026-07EUR 82.80$13.3 B+3.0%
- 2026-06EUR 80.35$12.9 B+9.4%
- 2026-05EUR 73.45$11.8 B+1.7%
- 2026-04EUR 72.20$11.6 B+5.6%
- 2026-03EUR 68.40$11 B-9.2%
- 2026-02EUR 75.30$12.1 B+0.7%
- 2026-01EUR 74.80$12 B-4.1%
- 2025-12EUR 78.00$12.5 B—
Ownership & Control
Latest available filings- Controlling entity
- Publicly held — no controlling shareholder disclosed
- Company type
- Brand & Manufacturer
- Insiders
- —
- Institutions
- —
- Free float
- —
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
In the press
All coverage →5 latest headlines2- Kerry stock buyback plan follows stronger Q3 volume growth - ad-hoc-news.dewww.ad-hoc-news.de2026-11-01
- Kerry Group plc (KRYAY) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canadaca.finance.yahoo.com2026-10-30
- Kerry Group plc (KRYAY) Q3 FY2026 earnings call transcript - Yahoo Financefinance.yahoo.com2026-10-27
- Kerry Group (OTCMKTS:KRYAY) Sees Unusually-High Trading Volume - Should You Buy? - MarketBeatwww.marketbeat.com2026-10-26
- Kerry Group Plc Sponsored ADR Estimates – SWB:KRZA - TradingViewwww.tradingview.com2026-10-24
Quick Facts
Headquarters
Tralee, County Kerry, Ireland
Founded
1972
Employees
23K+
Market cap
$15.7 B
Factories
150+
Presence
150+ Countries
Listing
Publicly Listed
Categories
13 categories · scroll for more
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $658 B
- Allergan Aesthetics· $521 B
- AbbVie Inc.· $521 B
- The Coca-Cola Company· $405 B
- F. Hoffmann-La Roche AG· $381 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Euronext Dublin : KRZ , Kerry Group Official Website
Grand View Research — Excipients Market Analysis
Mordor Intelligence — API Market
